CJC-1295 with DAC

• No body-composition, sleep, recovery, tissue-repair, anti-ageing or combination benefit has been established
• Scientifically supportable research uses include confirming DAC attachment and albumin-adduct formation, comparing defined DAC and no-DAC constructs, characterising GHRHR signalling, and studying formulation-specific aggregation, impurities and stability with appropriate controls.

CAS

446262-90-4

Formula

C₁₆₅H₂₆₉N₄₇O₄₆

Molecular weight

Approximately 3,647.2 Da

Appearance

Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA

Purity

Lot-specific released result; request raw chromatography, content assay and orthogonal identity data · target, verify batch COA

Storage

Store and ship according to the batch COA and validated stability data for the exact DAC form, counterion, formulation, concentration and container. Generic 2-8 degrees Celsius, minus 20 degrees Celsius and post-reconstitution periods are not interchangeable. Avoid unvalidated freeze-thaw cycles and record temperature excursions.

MOQ

On request

Lead time

10–18 days

CJC-1295 with DAC is a tetrasubstituted GRF(1-29) analogue bearing a C-terminal maleimidopropionyl Drug Affinity Complex. Jetté et al. demonstrated albumin-associated bioconjugation and prolonged activity in rats. Small 2006 studies of the defined investigational DAC molecule in healthy adults reported a terminal half-life of 5.8–8.1 days and prolonged GH and IGF-1 responses; a companion study found that GH pulsatility persisted during continuous stimulation. These results do not establish an approved treatment, a dosing schedule, equivalence of a commercial research vial or pharmacokinetics for no-DAC material. On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted against placing each reviewed CJC-1295 free-base, acetate and DAC form on the Section 503A Bulks List; the votes are advisory and do not themselves constitute a final FDA determination.

• Published evidence covers short Phase 1 pharmacokinetic and GH/IGF-1 response studies in healthy adults plus animal mechanism work
• It does not establish an approved indication, body-composition benefit, anti-aging effect, tissue-repair effect or clinical value of combining CJC-1295 with another secretagogue
• FDA's 2024 Section 503A review is regulatory safety and suitability context, not a research indication.

The peptide backbone is intended to agonise GHRHR. The maleimidopropionyl DAC group is designed to react with the free thiol at albumin Cys34, producing an albumin-associated conjugate that changes exposure. Jetté et al. supplied preclinical rat evidence for albumin association and prolonged biological activity; Teichman et al. supplied human pharmacokinetic and pharmacodynamic evidence for the defined investigational DAC molecule. Neither source proves that every commercially labelled vial contains an intact, correctly attached and functionally equivalent DAC construct. The companion human study reported preserved GH pulsatility, so a blanket claim that DAC converts secretion into a non-pulsatile state is not supported.

• CJC-1295 with DAC is not FDA-approved and lacks long-term human safety evidence
• The published healthy-adult studies were small and short
• FDA's official 2024 briefing identified aggregation, peptide-related impurities, immunogenicity, nonclinical toxicity and limited clinical evidence as material concerns
• Final PCAC minutes record 0 yes to 13 no votes on placing each reviewed DAC free-base, acetate and trifluoroacetate form on the Section 503A Bulks List; committee advice is non-binding
• FDA's current significant-safety-risk page also states that compounded CJC-1295 may pose immunogenicity and characterization risks, that available clinical data are limited, and that serious adverse events including increased heart rate and systemic vasodilatory reaction have been identified
• A 2006 lipodystrophy study was halted after a participant death, but a contemporaneous news report alone does not establish that CJC-1295 caused the death
• CJC-1295 is prohibited at all times under WADA 2026 S2.2.4
• Injection, GH-axis, glucose, fluid-retention or IGF-1 risks cannot be managed through vendor instructions

Interactions reported in the literature

• No controlled human combination protocol was located
• Theoretical dual activation of GHRH and ghrelin-receptor pathways does not establish the safety or efficacy of pairing CJC-1295 with ipamorelin, hexarelin, GHRP-2 or GHRP-6
• Its long exposure increases the importance of avoiding unsupported stack claims rather than validating them.

CJC-1295 with DAC2 mg · WHJLP-CD2-260320-C

CJC-1295 with DAC5 mg · WHJLP-CD5-260320-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• A supplier must prove the DAC-containing 30-residue construct rather than the no-DAC 29-residue peptide
• Require the complete sequence and maleimidopropionyl attachment, counterion, high-resolution intact mass, sequence-confirming MS/MS or orthogonal mapping, chromatographic purity with raw chromatograms and impurity profile, quantitative peptide content, aggregate and particle analysis, residual solvents, water/counterion content, and lot-specific stability
• Sterility, endotoxin and container-closure claims require separate validated evidence
• Clear appearance or a nominal approximately 3647 Da peak alone does not establish purity, correct attachment or low immunogenicity risk.

Store and ship according to the batch COA and validated stability data for the exact DAC form, counterion, formulation, concentration and container. Generic 2-8 degrees Celsius, minus 20 degrees Celsius and post-reconstitution periods are not interchangeable. Avoid unvalidated freeze-thaw cycles and record temperature excursions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• Primary evidence: Jetté et al., Endocrinology 2005, DOI 10.1210/en.2004-1286, for preclinical albumin bioconjugation and prolonged activity; Teichman et al., JCEM 2006, DOI 10.1210/jc.2005-1536, for human pharmacokinetics and GH/IGF-1 responses of the defined long-acting CJC-1295; Ionescu and Frohman, JCEM 2006, DOI 10.1210/jc.2006-1702, for preserved GH pulsatility during continuous stimulation. PubChem CID 91971820 and CID 91976842 distinguish DAC and no-DAC catalogue chemistry. FDA's official December 4, 2024 briefing and final PCAC minutes provide the compounding review, evidence limitations and form-specific votes; FDA's current significant-safety-risk page provides ongoing agency risk context. WADA's official 2026 Prohibited List supplies the current anti-doping classification. These sources do not qualify a supplied lot or create an approved use.

1. 01

   Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

   The Journal of Clinical Endocrinology & Metabolism (Oxford Academic / Endocrine Society) · 2006 · peer-reviewed original research (Phase 1, randomized, double-blind, placebo-controlled ascending-dose trials in humans)

   Open source
2. 02

   Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog

   The Journal of Clinical Endocrinology & Metabolism (Oxford Academic / Endocrine Society) · 2006 · peer-reviewed original research (mechanistic sub-study of the CJC-1295 human Phase 1 program)

   Open source
3. 03

   Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analog, Normalizes Growth in the GHRH Knockout Mouse

   American Journal of Physiology - Endocrinology and Metabolism · 2006 · peer-reviewed original research (preclinical, animal model)

   Open source
4. 04

   Identification of CJC-1295, a Growth-Hormone-Releasing Peptide, in an Unknown Pharmaceutical Preparation

   Drug Testing and Analysis (Wiley, published on behalf of anti-doping science community) · 2010 · peer-reviewed original research (analytical/forensic chemistry, anti-doping)

   Open source
5. 05

   Lipodystrophy study halted after patient death

   aidsmap (NAM Publications) - established HIV/AIDS medical news service · 2006 · trade/medical news journalism (contemporaneous report on a halted Phase II trial)

   Open source
6. 06

   FDA Briefing Document: CJC-1295-Related Bulk Drug Substances

   U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee · 2024 · regulatory assessment (official U.S. FDA briefing document)

   Open source
7. 07

   Final Summary Minutes of the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting

   U.S. Food and Drug Administration · 2025 · official advisory committee meeting record

   Open source
8. 08

   CJC-1295, PubChem CID 91971820

   PubChem Compound Database (National Institutes of Health / NCBI) · 2026 · reference database entry (U.S. government scientific database, NIH/NCBI)

   Open source